Developer docs
API playgroundTry for free, no card

Search company profiles

Cure Forward

Full company profile

uuid0005fo8

Namestring
Cure Forward
Websiteurl
cureforward.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Cure Forward was a Boston-based, for-profit private company founded in 2014 that operated in the oncology patient-access space. Per its firmographic short description, the company helped cancer patients and physicians access advanced treatments in oncology — functionally a service connecting patients and providers to oncology clinical-trial and treatment pathways. Detailed product architecture, technology stack, integration points, and revenue mechanics are not documented in the available inputs; no specific products, APIs, SDKs, or platform modules are enumerated across the sourced material.

The company was capitalized through approximately $27.8M across four funding events between 2015 and 2017. The largest single event was a $15,000,000 round on 2015-06-18 led by Apple Tree Partners, a healthcare-specialist investor, with three subsequent financings of roughly $4M–$4.5M each through May 2017. The leadership team — CEO Frank Ingari, CFO Sean Bridgeo, and CMO Stacey Santo — was assembled during the growth phase, but no subsequent hires, partnerships, product launches, customer wins, or M&A activity are documented after May 2017.

The most operationally significant present-day signal is that CureForward.com is listed for sale on HugeDomains at $19,195 ($799.79/month for 24 months). This is an anomalous fact: the active listing of a company's primary domain on a domain marketplace is consistent with a wind-down, divestiture, or — at minimum — abandonment of the digital surface. The source explicitly notes this does not conclusively prove the entity has ceased operations, but in the absence of any other operating evidence for ~7+ years, this is the dominant signal in the dataset.

Short descriptiontext

Cure Forward is a Boston-based private company founded in 2014 that helps cancer patients and physicians access advanced oncology treatments, having raised approximately $27.8M across four funding rounds led by Apple Tree Partners between 2015 and 2017.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
oncology patient access, clinical trial matching, cancer treatment platform, precision oncology services, patient recruitment platform
Industry2 codes
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLALAFAD
Oncology Remote Symptom Monitoring & Care Navigation
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SIC code1 code
  • Services-Health Services8000
Product category
Oncology Patient Treatment Access
Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Core offering1 text field

Cure Forward operates a platform that connects cancer patients and their physicians with advanced oncology treatments. The service facilitates access to precision oncology options, including clinical trials and emerging therapies, by linking patients to relevant treatment opportunities beyond standard care.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No product or service information is available. The source data indicates CureForward.com is a domain name listed for sale on HugeDomains.com for $19,195. No information about Cure Forward's actual products, services, or business offerings is present in the provided source material.

Product and service1 record
1Oncology Treatment Access Platform
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven oncology clinical trial matching platform connecting cancer patients with appropriate trials. Directly comparable to Cure Forward's oncology-treatment-access mission and similar target user (oncology patients + referring physicians).

2Tempus Labs
TypeBroad incumbent
Description

AI-powered precision medicine platform with extensive oncology data, sequencing, and clinical-trial matching capabilities. Much larger incumbent operating across the same oncology-treatment-access value chain.

TypeDirect peer
Description

Digital clinical trial matching and patient-recruitment company that built a precision-medicine patient-finding engine for pharma sponsors. Overlaps with Cure Forward's use of clinical data to connect patients with advanced treatments.

TypeDirect peer
Description

Patient engagement and care management platform purpose-built for oncology, including symptom management and clinical trial awareness. Closely adjacent to Cure Forward's oncology patient-navigation focus.

TypeDirect peer
Description

Clinical trial matching with an emphasis on ensuring diverse patient enrollment. Operates in the same patient-to-trial matching category as Cure Forward and serves similar pharma sponsor and patient users.

TypeDirect peer
Description

Patient-first clinical trial matching platform focused on reducing barriers to trial enrollment. Directly comparable as a digital health intermediary that helps patients access advanced therapies, including oncology.

TypeBroad incumbent
Description

Roche-owned oncology-specific EHR and real-world data platform connecting providers, patients, and pharma researchers. A broad oncology platform incumbent whose treatment-access and trial-recruitment capabilities overlap with Cure Forward's mission at much larger scale.

TypeEmerging player
Description

Direct-to-patient oncology app that combines treatment options, clinical trial matching, and care navigation for cancer patients. Overlaps meaningfully with Cure Forward's patient-side treatment-access offerings.

9Deep 6 AI
TypeDirect peer
Description

AI platform that mines clinical records to match patients to trials and accelerate study recruitment. Strong direct peer — both companies use data-driven matching to route patients toward advanced oncology and specialty treatments.

10Mendel.ai
TypeDirect peer
Description

AI-powered oncology clinical trial matching and patient cohort identification, focused on oncology and rare diseases. Directly overlaps with Cure Forward's cancer-treatment-access proposition.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cure Forward

Oncology Patient Treatment Accesscureforward.com

Cure Forward is a Boston-based private company founded in 2014 that helps cancer patients and physicians access advanced oncology treatments, having raised approximately $27.8M across four funding rounds led by Apple Tree Partners between 2015 and 2017.

What Cure Forward does

Cure Forward was a Boston-based, for-profit private company founded in 2014 that operated in the oncology patient-access space. Per its firmographic short description, the company helped cancer patients and physicians access advanced treatments in oncology — functionally a service connecting patients and providers to oncology clinical-trial and treatment pathways. Detailed product architecture, technology stack, integration points, and revenue mechanics are not documented in the available inputs; no specific products, APIs, SDKs, or platform modules are enumerated across the sourced material.

The company was capitalized through approximately $27.8M across four funding events between 2015 and 2017. The largest single event was a $15,000,000 round on 2015-06-18 led by Apple Tree Partners, a healthcare-specialist investor, with three subsequent financings of roughly $4M–$4.5M each through May 2017. The leadership team — CEO Frank Ingari, CFO Sean Bridgeo, and CMO Stacey Santo — was assembled during the growth phase, but no subsequent hires, partnerships, product launches, customer wins, or M&A activity are documented after May 2017.

The most operationally significant present-day signal is that CureForward.com is listed for sale on HugeDomains at $19,195 ($799.79/month for 24 months). This is an anomalous fact: the active listing of a company's primary domain on a domain marketplace is consistent with a wind-down, divestiture, or — at minimum — abandonment of the digital surface. The source explicitly notes this does not conclusively prove the entity has ceased operations, but in the absence of any other operating evidence for ~7+ years, this is the dominant signal in the dataset.

Cure Forward firmographics

Firmographics
Name
Cure Forward
Website
https://cureforward.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Cure Forward is a Boston-based private company founded in 2014 that helps cancer patients and physicians access advanced oncology treatments, having raised approximately $27.8M across four funding rounds led by Apple Tree Partners between 2015 and 2017.
Ownership category
akta.pro rank

Cure Forward industry classification

Industry
Product category
Oncology Patient Treatment Access
SIC
Services-Health Services (8000)
akta.pro industry
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLALAFAD
Oncology Remote Symptom Monitoring & Care Navigation
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

  • Oncology patient access
  • Clinical trial matching
  • Cancer treatment platform
  • Precision oncology services
  • Patient recruitment platform

Where Cure Forward is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

Cure Forward business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Cure Forward product offering

Product offering

Core offering

Cure Forward operates a platform that connects cancer patients and their physicians with advanced oncology treatments. The service facilitates access to precision oncology options, including clinical trials and emerging therapies, by linking patients to relevant treatment opportunities beyond standard care.

Product overview

No product or service information is available. The source data indicates CureForward.com is a domain name listed for sale on HugeDomains.com for $19,195. No information about Cure Forward's actual products, services, or business offerings is present in the provided source material.

Differentiator

Problem solved

Functional benefit

Products and services

  • Oncology Treatment Access Platform

Companies that use Cure Forward

Customer profile

Ideal customer profiles2 records

Cure Forward technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Cure Forward partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights3 records

Cure Forward competitors and assessment

Company assessment

Direct peers

  • Massive Bio: AI-driven oncology clinical trial matching platform connecting cancer patients with appropriate trials. Directly comparable to Cure Forward's oncology-treatment-access mission and similar target user (oncology patients + referring physicians).
  • Antidote: Digital clinical trial matching and patient-recruitment company that built a precision-medicine patient-finding engine for pharma sponsors. Overlaps with Cure Forward's use of clinical data to connect patients with advanced treatments.
  • Navigating Cancer: Patient engagement and care management platform purpose-built for oncology, including symptom management and clinical trial awareness. Closely adjacent to Cure Forward's oncology patient-navigation focus.
  • Trial Library: Clinical trial matching with an emphasis on ensuring diverse patient enrollment. Operates in the same patient-to-trial matching category as Cure Forward and serves similar pharma sponsor and patient users.
  • Clara Health: Patient-first clinical trial matching platform focused on reducing barriers to trial enrollment. Directly comparable as a digital health intermediary that helps patients access advanced therapies, including oncology.
  • Deep 6 AI: AI platform that mines clinical records to match patients to trials and accelerate study recruitment. Strong direct peer — both companies use data-driven matching to route patients toward advanced oncology and specialty treatments.
  • Mendel.ai: AI-powered oncology clinical trial matching and patient cohort identification, focused on oncology and rare diseases. Directly overlaps with Cure Forward's cancer-treatment-access proposition.

Broad incumbents

  • Tempus Labs: AI-powered precision medicine platform with extensive oncology data, sequencing, and clinical-trial matching capabilities. Much larger incumbent operating across the same oncology-treatment-access value chain.
  • Flatiron Health: Roche-owned oncology-specific EHR and real-world data platform connecting providers, patients, and pharma researchers. A broad oncology platform incumbent whose treatment-access and trial-recruitment capabilities overlap with Cure Forward's mission at much larger scale.

Emerging players

  • Outcomes4Me: Direct-to-patient oncology app that combines treatment options, clinical trial matching, and care navigation for cancer patients. Overlaps meaningfully with Cure Forward's patient-side treatment-access offerings.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Cure Forward social profiles

Digital presence

Cure Forward financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cure Forward leadership team

Management profile

Number of profiles

Profiles3 records

Cure Forward funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cure Forward M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cure Forward

What does Cure Forward do?

Cure Forward operates a platform that connects cancer patients and their physicians with advanced oncology treatments. The service facilitates access to precision oncology options, including clinical trials and emerging therapies, by linking patients to relevant treatment opportunities beyond standard care.

When was Cure Forward founded?

Cure Forward was founded in 2014. It employs 11 to 50 people.

Where is Cure Forward based?

Cure Forward is headquartered in Boston, United States, in the North America region.

Who are Cure Forward's main competitors?

Direct peers on record are Massive Bio, Antidote, Navigating Cancer, Trial Library, Clara Health, Deep 6 AI and Mendel.ai. Broad incumbents are Tempus Labs and Flatiron Health. Outcomes4Me is listed as an emerging player.

Does Cure Forward have an API?

No public API is recorded for Cure Forward.

What industry is Cure Forward in?

Cure Forward's product category is Oncology Patient Treatment Access. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support, with a secondary code of HLALAFAD, Oncology Remote Symptom Monitoring & Care Navigation. Its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrwebArrowhead Publishers Announces the Speaking Faculty for the 9th Annual Personalized & Precision Medicine Conference in OrlandoArrowhead Publishers announced the speaking faculty for its 9th Annual Personalized & Precision Medicine Conference in Orlando, October 16-17, 2017, as a satellite event to the American Society of Human Genetics meeting. The conference covers R&D, technologies, infectious disease, CNS and cardiovascular disease, patient engagement, and clinical adoption.PR NewswireFight Colorectal Cancer Partners With Cure Forward To Improve Patient Access To Leading Edge Cancer TreatmentsFight Colorectal Cancer and Cure Forward announced a partnership to give colorectal cancer patients free access to advanced clinical trial treatments. The collaboration provides one-on-one assistance via Cure Forward's Clinical Trial Navigators and integrates Fight CRC resources. The partnership aims to help patients navigate the complex landscape of clinical trial access.PR NewswireFight Colorectal Cancer Partners With Cure Forward To Improve Patient Access To Leading Edge Cancer TreatmentsFight Colorectal Cancer and Cure Forward announced a strategic partnership to help colorectal cancer patients access advanced treatment options available through clinical trials at no cost. Through the partnership, patients accessing Cure Forward's platform via Fight CRC will receive assistance from Clinical Trial Navigators who help build personalized profiles to identify relevant clinical trials. Fight CRC, a national nonprofit advocacy organization, and Cure Forward, a healthcare platform company, aim to address the gap where patients lack tools to find and navigate clinical trial options.PR NewswireCure Forward Selects Personal Genome Diagnostics as a Provider of Genomic Data to Cancer Patients Using Its Platform to Access Precision Medicine Treatment OptionsCure Forward and Personal Genome Diagnostics announced an agreement enabling cancer patients on the Cure Forward platform to select PGDx for genomic testing. PGDx will provide results in interoperable formats for patient use, with data reported to physicians via diagnostic reports. The collaboration aims to expand patient access to precision medicine.PR NewswireCure Forward Selects Personal Genome Diagnostics as a Provider of Genomic Data to Cancer Patients Using Its Platform to Access Precision Medicine Treatment OptionsCure Forward and Personal Genome Diagnostics Inc. (PGDx) have entered into an agreement to enable cancer patients using the Cure Forward Patient Activation platform to select PGDx for genomic testing services. This partnership allows patients to access their genomic testing results directly through the Cure Forward platform, facilitating better engagement in their treatment options. The collaboration aims to enhance patient access to precision medicine and potentially accelerate research towards improved cancer treatments.PR NewswireOmniSeq Receives New York CLEP Approval For 144 Gene Comprehensive Panel And Partners With Cure Forward To Advance Precision Medicine For Cancer PatientsOmniSeq, a Roswell Park Cancer Institute subsidiary, received New York State CLEP approval for its OmniSeq Comprehensive panel, a 144-gene pan-cancer NGS tumor profiling test. The panel provides access to over 650 therapeutic associations and 850 clinical trial associations, and OmniSeq partnered with Cure Forward to help patients access clinical trials.PR NewswireOmniSeq Receives New York CLEP Approval For 144 Gene Comprehensive Panel And Partners With Cure Forward To Advance Precision Medicine For Cancer PatientsOmniSeq, a subsidiary of Roswell Park Cancer Institute, received New York State CLEP approval for its OmniSeq Comprehensive 144-gene pan-cancer tumor profiling panel, which guides oncology treatment decisions by providing access to over 650 therapeutic associations and 850 clinical trial associations. The panel was developed using Thermo Fisher Scientific's Oncomine reagents and Ion Torrent sequencing system, the same technology used by the National Cancer Institute's MATCH trial. OmniSeq also announced a partnership with Cure Forward to help cancer patients access clinical trials through Cure Forward's Clinical Trial Exchange platform.socaltech.comCynvenio Links With Cure ForwardCynvenio Biosystems linked with Cure Forward to help cancer patients use its ClearID genomic test. The partnership was not disclosed financially, and Cynvenio raised $25.5M in venture funding earlier this week.FinSMEsCure Forward Secures $15M in Series A Financing - FinSMEsCure Forward, a New York City-based patient activation company, secured $15M in Series A financing from Apple Tree Partners. The funds will build a multisided healthcare platform based on precision medicine, with a private beta and September 2015 launch.